Nektar Announces Publication In Blood Of Phase 1 Data For Novel IL-15 Agonist NKTR-255 In Combination With Autologous CD19-22 CAR-T Cell Therapy In Patients With B-cell Acute Lymphoblastic Leukemia
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics announced positive Phase 1 data for its novel IL-15 agonist NKTR-255 in combination with CAR-T cell therapy for B-cell acute lymphoblastic leukemia, showing improved survival rates and remission.

October 17, 2024 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nektar Therapeutics' NKTR-255, in combination with CAR-T cell therapy, demonstrated significant efficacy in a Phase 1 study for B-cell acute lymphoblastic leukemia, doubling 12-month survival rates compared to historical controls.
The publication of positive Phase 1 data for NKTR-255 in combination with CAR-T therapy indicates a significant advancement in treatment efficacy for B-cell acute lymphoblastic leukemia. The doubling of survival rates compared to historical controls is likely to boost investor confidence and positively impact Nektar's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100